Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

The null hypothesis for the primary endpoint was that the mean change in HbA1c from baseline to Week 24 in the bexagliflozin arm would be equal to or greater than the mean change in the placebo arm.

Region, baseline eGFR categories and BMI, history of heart failure, insulin use (Y/N), treatment, visit and baseline HbA1c as fixed effect covariate.

P-value is based on one sided statistical tests using a 0.025 level of significance.

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

This group includes all subjects who have received bexagliflozin in the study.

Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Placebo: 20 mg tablet to match active comparator

This group includes all subjects who have received placebo in the study.

Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.

Bexagliflozin: 20 mg, tablet

This group includes subjects who reported a history of heart failure and randomized to the bexagliflozin arm.